Expert Interview
Discussing the Phase 3 CORALreef HeFH trial results evaluating enlicitide decanoate, Merck’s once-daily oral PCSK9 inhibitor, in adults with heterozygous familial hypercholesterolemia (HeFH).
Ticker(s): MRKInstitution: University of Kansas Medical Center
- Professor of Medicine at The University of Kansas Medical Center in Kansas City and Director of Clinical Pharmacology and the Atherosclerosis and Lipid-Apheresis Center
- Treats hundreds of patients with HeFH
- Published over 100 peer reviewed articles/chapters and participated in numerous clinical trials related to dyslipidemia, Lp(a), obesity, hypertension, and diabetes; Research activities include such topics as atherosclerosis, familial hypercholesterolemia, Lp(a), Lipoprotein-Apheresis, vascular Inflammation, dementia and hemorheology
How does the efficacy of enlicitide in reducing LDL cholesterol levels in the CORALreef trials influence your confidence in its potential as a first-line oral therapy for hyperlipidemia patients already on statins?
Added By: sara_adminDid anything in the safety or tolerability profile of enlicitide decanoate from CORALreef HeFH stand out to you—either positively or negatively—especially regarding long-term use in younger HeFH patients?
Added By: sara_adminIf enlicitide decanoate were approved with the efficacy shown in CORALreef HeFH, how would you envision incorporating a once-daily oral PCSK9 inhibitor into your treatment algorithm for HeFH patients who remain above goal on statins and ezetimibe?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
